Over the past few years, the medical community has seen an increasing number of trials emerging for SGLT2 inhibitors and GLP-1 receptor agonist agents demonstrating positive results in reducing the risk for patients with cardiovascular disease and diabetes.

Stay up to date with ACC's new webpage, Cardiovascular Risk in Diabetes: Applying Emerging Science to Practice.

The goal of the page is to assemble the most relevant resources to educate the cardiovascular community on the latest scientific developments in cardiovascular risk in diabetes and make this information easily accessible for greater adoption into clinical practice.

The page will be updated to include new developments as they are published. Learn more.